CFDA approves Elekta's sales and marketing in China

Following the United States and Europe's approval of Elekta's Versa HD linear accelerator, the Chinese Food and Drug Administration (CFDA) has approved the radiotherapy system for sale and marketing in China.

According to the International Agency for Research on Cancer, China has more than 3 million patients diagnosed with cancer each year1. The most common types of cancer include lung cancer, stomach cancer, colorectal cancer, liver cancer, and esophageal cancer2. Versa HD is designed to increase the level of treatment for patients and has a wider range of treatments for cancer treatment in multiple body parts of the body.

The Versa HD is equipped with AgilityTM multi-leaf collimator for high-speed, high-precision beamforming to assist in extremely precise tumor-targeted therapy and enhance protection of healthy tissues. Used in conjunction with high-dose-rate treatment modes, Versa HD can optimize clinical workflows by quickly providing more advanced therapies within the standard radiotherapy time.

Mr. Gong Anming, President of Medical Keda China, said: "As China's cancer incidence continues to rise, the demand for advanced and effective treatment is growing. Versa HD will help promote the Chinese government's health care reform. This reform will include the 2020. Annual medical and health care for urban and rural residents."

Since its launch in 2013, Versa HD has been very popular and sold in 30 countries. Medical Kodak has been doing business in China since 1982, and 8 of the top 10 cancer centers in China use Elcoteq's linear accelerators. Launch of Versa HD will strengthen Elekta’s leadership in the Chinese market